Adagrasib exhibited an intracranial ORR of 33.3% (94% CI 18.0–51.8) among 33 patients with NSCLC with KRAS G12C mutations with previously treated stable BrMs [86]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.